GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » Price-to-Owner-Earnings

Krystal Biotech (FRA:4KB) Price-to-Owner-Earnings : (As of Jan. 18, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech Price-to-Owner-Earnings?

As of today (2025-01-18), Krystal Biotech's share price is €139.90. Krystal Biotech does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Krystal Biotech's Price-to-Owner-Earnings or its related term are showing as below:

During the past 8 years, the highest Price-to-Owner-Earnings of Krystal Biotech was 330.23. The lowest was 273.79. And the median was 297.37.


FRA:4KB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 29.67
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-01-18), Krystal Biotech's share price is €139.90. Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €1.62. Therefore, Krystal Biotech's PE Ratio (TTM) for today is 86.15.

As of today (2025-01-18), Krystal Biotech's share price is €139.90. Krystal Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was €2.66. Therefore, Krystal Biotech's PE Ratio without NRI for today is 52.61.

During the past 8 years, Krystal Biotech's highest PE Ratio without NRI was 226.10. The lowest was 51.03. And the median was 67.89.


Krystal Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Krystal Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Price-to-Owner-Earnings Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Krystal Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 283.33 -

Competitive Comparison of Krystal Biotech's Price-to-Owner-Earnings

For the Biotechnology subindustry, Krystal Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Price-to-Owner-Earnings falls into.



Krystal Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Krystal Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=139.90/-0.21
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Krystal Biotech  (FRA:4KB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Krystal Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Headlines

No Headlines